Skip to main content
. Author manuscript; available in PMC: 2010 Oct 15.
Published in final edited form as: J Immunol. 2009 Sep 28;183(8):5407–5417. doi: 10.4049/jimmunol.0901760

FIGURE 3.

FIGURE 3

HMBPP/IL-2 cotreatment only during chronic infection does not affect viral load or survival. Average SIVgag RNA copies per milliliter of plasma are shown over time for groups treated with HMBPP plus IL-2, IL-2 alone, or sham only during chronic infection (a). Arrow indicates the time when treatment was given. Percentages of surviving animals over time are shown for groups treated with HMBPP plus IL-2, IL-2 alone, or sham only during chronic infection at day 118 postinfection or during both acute and chronic infection at days −3, 17, and 102 postinfection (indicated with asterisks) (b).